NCT05743777 - PembROlizumab With or Without Microbial EcOsystem ThErapeutic 4 (MET4) in Advanced Head and Neck Squamous Cell Carcinoma | Biotech Hunter

Timeline

Start Date

May 12, 2023

Primary Completion Date

May 12, 2023

Study Completion Date

May 12, 2023

Conditions

Advanced Head and Neck Squamous Cell Carcinoma

Interventions

DRUG

Pembrolizumab

400 mg IV q6 weekly for a maximum of 18 cycles

DRUG

MET-4

Cycle 1: 5 g (10 capsules) on days -7 and -6 and 1.5 g (3 capsules) on day -5 and every day thereafter Cycle 2 onwards: 1.5 g (3 capsules) daily

DRUG

Placebo

Cycle 1: 5 g (10 capsules) on days -7 and -6 and 1.5 g (3 capsules) on day -5 and every day thereafter Cycle 2 onwards: 1.5 g (3 capsules) daily